CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon
Diabetes Metab J. 2021;45(6):954-959.   Published online November 12, 2020
DOI: https://doi.org/10.4093/dmj.2020.0173

Excel Download

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Diabetes & Metabolism Journal. 2021;45(6):954-959   Crossref logo
Link1 Link2 Link3

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
The Lancet. 2019;394(10208):1519-1529   Crossref logo
Link1 Link2

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
Diabetes, Obesity and Metabolism. 2009;11(5):506-515   Crossref logo
Link1 Link2

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
Diabetes Therapy. 2020;11(11):2465-2476   Crossref logo
Link1 Link2 Link3

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
Korean Diabetes Journal. 2010;34(6):331   Crossref logo
Link1 Link2 Link3

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin‐metformin combination in newly diagnosed Type 2 diabetes
Diabetic Medicine. 2019;36(4):505-513   Crossref logo
Link1 Link2 Link3 Link4

1159-P: Metformin Monotherapy Changes Gut Microbiota in Newly Diagnosed Type 2 Diabetes
Diabetes. 2019;68(Supplement_1):   Crossref logo
Link1 Link2

A strategy implementing initial therapy with a fixed- dose combination tablet of sitagliptin and metformin in patients with type 2 diabetes provides superior glycaemic control compared with a strategy using initial metformin monotherapy over 44 weeks
Canadian Journal of Diabetes. 2009;33(3):208-209   Crossref logo
Link1 Link2

Initial Combination with Linagliptin and Metformin in Newly Diagnosed Type 2 Diabetes and Severe Hyperglycemia
Advances in Therapy. 2012;29(12):1005-1015   Crossref logo
Link1 Link2 Link3

Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2012;125   Crossref logo
Link1